Lipid Formulations and Bioconjugation Strategies for Indomethacin Therapeutic Advances
Indomethacin (IND) is a drug which after successful clinical trials became available for general prescription in 1965 and from that time is one of the most widely used anti-inflammatory drug with the highest potencies in the in vitro and in vivo models. However, despite its high therapeutic efficacy...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-03-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/26/6/1576 |
| _version_ | 1797541559455973376 |
|---|---|
| author | Anna Gliszczyńska Marta Nowaczyk |
| author_facet | Anna Gliszczyńska Marta Nowaczyk |
| author_sort | Anna Gliszczyńska |
| collection | DOAJ |
| description | Indomethacin (IND) is a drug which after successful clinical trials became available for general prescription in 1965 and from that time is one of the most widely used anti-inflammatory drug with the highest potencies in the in vitro and in vivo models. However, despite its high therapeutic efficacy in relieving the symptoms of certain arthritis and in treating gout or collagen diseases, administration of IND causes a number of adverse effects, such as gastrointestinal ulceration, frequent central nervous system disorders and renal toxicity. These obstacles significantly limit the practical applications of IND and make that 10–20% of patients discontinue its use. Therefore, during the last three decades many attempts have been made to design novel formulations of IND aimed to increase its therapeutic benefits minimizing its adverse effects. In this review we summarize pharmacological information about IND and analyze its new lipid formulations and lipid bioconjugates as well as discuss their efficacy and potential application. |
| first_indexed | 2024-03-10T13:17:40Z |
| format | Article |
| id | doaj.art-b5dde11f244e491991c409bf22d687fa |
| institution | Directory Open Access Journal |
| issn | 1420-3049 |
| language | English |
| last_indexed | 2024-03-10T13:17:40Z |
| publishDate | 2021-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Molecules |
| spelling | doaj.art-b5dde11f244e491991c409bf22d687fa2023-11-21T10:18:45ZengMDPI AGMolecules1420-30492021-03-01266157610.3390/molecules26061576Lipid Formulations and Bioconjugation Strategies for Indomethacin Therapeutic AdvancesAnna Gliszczyńska0Marta Nowaczyk1Department of Chemistry, Wrocław University of Environmental and Life Sciences, Norwida 25, 50-375 Wrocław, PolandDepartment of Chemistry, Wrocław University of Environmental and Life Sciences, Norwida 25, 50-375 Wrocław, PolandIndomethacin (IND) is a drug which after successful clinical trials became available for general prescription in 1965 and from that time is one of the most widely used anti-inflammatory drug with the highest potencies in the in vitro and in vivo models. However, despite its high therapeutic efficacy in relieving the symptoms of certain arthritis and in treating gout or collagen diseases, administration of IND causes a number of adverse effects, such as gastrointestinal ulceration, frequent central nervous system disorders and renal toxicity. These obstacles significantly limit the practical applications of IND and make that 10–20% of patients discontinue its use. Therefore, during the last three decades many attempts have been made to design novel formulations of IND aimed to increase its therapeutic benefits minimizing its adverse effects. In this review we summarize pharmacological information about IND and analyze its new lipid formulations and lipid bioconjugates as well as discuss their efficacy and potential application.https://www.mdpi.com/1420-3049/26/6/1576bioconjugatesindomethacinlipid-based formulationsprodrugsdrug-phospholipid conjugatesliposomes |
| spellingShingle | Anna Gliszczyńska Marta Nowaczyk Lipid Formulations and Bioconjugation Strategies for Indomethacin Therapeutic Advances Molecules bioconjugates indomethacin lipid-based formulations prodrugs drug-phospholipid conjugates liposomes |
| title | Lipid Formulations and Bioconjugation Strategies for Indomethacin Therapeutic Advances |
| title_full | Lipid Formulations and Bioconjugation Strategies for Indomethacin Therapeutic Advances |
| title_fullStr | Lipid Formulations and Bioconjugation Strategies for Indomethacin Therapeutic Advances |
| title_full_unstemmed | Lipid Formulations and Bioconjugation Strategies for Indomethacin Therapeutic Advances |
| title_short | Lipid Formulations and Bioconjugation Strategies for Indomethacin Therapeutic Advances |
| title_sort | lipid formulations and bioconjugation strategies for indomethacin therapeutic advances |
| topic | bioconjugates indomethacin lipid-based formulations prodrugs drug-phospholipid conjugates liposomes |
| url | https://www.mdpi.com/1420-3049/26/6/1576 |
| work_keys_str_mv | AT annagliszczynska lipidformulationsandbioconjugationstrategiesforindomethacintherapeuticadvances AT martanowaczyk lipidformulationsandbioconjugationstrategiesforindomethacintherapeuticadvances |